Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KTX-0141
- Development stage
- Preclinical
- Lead developer
- Kasvu Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KTX-0141 is a preclinical-stage, small-molecule positive allosteric modulator (PAM) of tropomyosin receptor kinase B (TrkB) being developed by Kasvu Therapeutics for the treatment of major depressive disorder (MDD). Originating from research at the University of Helsinki, KTX-0141 is designed to selectively amplify endogenous brain-derived neurotrophic factor (BDNF) signaling at TrkB, promoting neuroplasticity pathways associated with rapid and long-lasting antidepressant effects. Unlike traditional psychedelics, KTX-0141 does not engage the 5-HT2A serotonin receptor, thereby avoiding hallucinogenic side effects and potentially enabling at-home administration.
02
Targets
NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on KTX-0141.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KTX-0141.